Vertex Pharmaceuticals Receives FDA Approval for Journavx in Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals today announced that the FDA has approved Journavx (suzetrigine) for the treatment of moderate-to-severe acute pain in adults. This marks the first approval of a new class of pain medicine in over 20 years and the first non-opioid acute pain treatment with a novel mechanism of action. Journavx is a highly selective Nav1.8 sodium channel inhibitor that blocks pain signals in peripheral sensory neurons without the addiction risk associated with opioids. In Phase 3 trials, Journavx demonstrated significant pain relief compared to placebo with a favorable safety profile.